Examining the Use of Real‐World Evidence in the Regulatory Process-Reference-Cited by-同舟云学术

Examining the Use of Real‐World Evidence in the Regulatory Process

Published:2019-11-14 Issue:4 Volume:107 Page:843-852
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Beaulieu‐Jones Brett K.¹^ORCID,Finlayson Samuel G.¹,Yuan William¹,Altman Russ B.²^ORCID,Kohane Isaac S.¹,Prasad Vinay³,Yu Kun‐Hsing¹^ORCID

Affiliation:

1. Department of Biomedical Informatics Harvard Medical School Boston Massachusetts USA

2. Departments of Bioengineering, Genetics, Medicine, and Biomedical Data Science Stanford University Stanford California USA

3. Division of Hematology Oncology Department of Public Health and Preventive Medicine Center for Health Care Ethics Knight Cancer Institute Oregon Health & Science University Portland Oregon USA

Funder

U.S. National Library of Medicine

National Institute of General Medical Sciences

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1658

Reference121 articles.

1. Multidimensional Evidence Generation and FDA Regulatory Decision Making

2. Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness

3. US Food and Drug Administration.Real‐world evidence (2019).

4. Real‐World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe

5. Real-World Evidence — What Is It and What Can It Tell Us?

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficient capture of dry eye data from the real world: The Save Sight Dry Eye Registry;AJO International;2024-10

2. Health technology assessments of new specialized therapies: A typology of key challenges and potential policy solutions;Health Policy and Technology;2024-09

3. A Two‐Step Framework for Validating Causal Effect Estimates;Pharmacoepidemiology and Drug Safety;2024-09

4. Exploring Novel Adverse Events of Nefecon;Kidney International Reports;2024-09

5. Transparency in the secondary use of health data: Assessing the status quo of guidance and best practices;2024-08-11